Derek Thomas O'hagan

Derek Thomas O'hagan's AcademicInfluence.com Rankings

Biology

#9274

World Rank

#12460

Historical Rank

Immunology

#553

World Rank

#571

Historical Rank

biology Degrees

Download Badge

Biology

Derek Thomas O'hagan's Degrees

Bachelors Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Derek Thomas O'hagan Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Derek Thomas O'hagan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome (2009) (519)
Advances in vaccine adjuvants (1999) (498)
Cationic microparticles: A potent delivery system for DNA vaccines. (2000) (472)
Nonviral delivery of self-amplifying RNA vaccines (2012) (465)
Molecular and cellular signatures of human vaccine adjuvants (2008) (451)
Recent advances in the discovery and delivery of vaccine adjuvants (2003) (412)
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. (2011) (370)
Emerging concepts in the science of vaccine adjuvants (2021) (327)
Recent developments in adjuvants for vaccines against infectious diseases. (2001) (320)
The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells1 (2008) (292)
Biodegradable microparticles as controlled release antigen delivery systems. (1991) (277)
Recent Advances in Vaccine Adjuvants (2002) (275)
The path to a successful vaccine adjuvant--'the long and winding road'. (2009) (268)
MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection (2007) (252)
The history of MF59® adjuvant: a phoenix that arose from the ashes (2013) (249)
A cationic nanoemulsion for the delivery of next-generation RNA vaccines. (2014) (230)
The Preparation and Characterization of Poly(lactide-co-glycolide) Microparticles. II. The Entrapment of a Model Protein Using a (Water-in-Oil)-in-Water Emulsion Solvent Evaporation Technique (1993) (228)
Microparticles as vaccine adjuvants and delivery systems (2003) (220)
Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want (2018) (206)
The preparation and characterisation of poly(lactide-co-glycolide) microparticles. I: Oil-in-water emulsion solvent evaporation (1991) (199)
Recent advances in veterinary vaccine adjuvants. (2003) (196)
Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. (1994) (190)
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity (2021) (188)
Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant (2009) (185)
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. (2008) (183)
Enhancement of DNA vaccine potency in rhesus macaques by electroporation. (2004) (182)
Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines (2001) (180)
Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. (1993) (180)
Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. (1992) (178)
Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. (1995) (173)
Microparticle-based technologies for vaccines. (2006) (171)
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88 (2011) (168)
Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells (2000) (164)
The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. (2013) (155)
Controlled release microparticles for vaccine development. (1991) (153)
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells (2009) (153)
Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake (2017) (152)
Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus (2015) (151)
Novel Approaches to Vaccine Delivery (2004) (150)
Rational design of small molecules as vaccine adjuvants (2014) (149)
Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. (1996) (149)
Novel Delivery Systems for Oral Vaccines (1994) (143)
Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, and Unrelated Adjuvants (2000) (138)
The vaccine adjuvant alum inhibits IL‐12 by promoting PI3 kinase signaling while chitosan does not inhibit IL‐12 and enhances Th1 and Th17 responses (2012) (137)
Biodegradable microparticles for oral immunization. (1993) (136)
A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. (2001) (135)
Microparticles for the delivery of DNA vaccines (2004) (134)
New generation adjuvants--from empiricism to rational design. (2015) (133)
Mechanism of action of mRNA-based vaccines (2017) (132)
MF59 adjuvant: the best insurance against influenza strain diversity (2011) (131)
Designing and building the next generation of improved vaccine adjuvants. (2014) (130)
Vaccine adjuvants : preparation methods and research protocols (2000) (130)
Vaccine adjuvant formulations: a pharmaceutical perspective. (2013) (128)
Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. (1990) (128)
Intestinal translocation of particulates — implications for drug and antigen delivery (1990) (122)
Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. (2006) (122)
Cationic Microparticles Are an Effective Delivery System for Immune Stimulatory CpG DNA (2001) (121)
Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. (2000) (119)
The long-term potential of biodegradable poly(lactideco-glycolide) microparticles as the next-generation vaccine adjuvant (2011) (117)
CpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine (2005) (116)
Mucosal adjuvants and delivery systems for protein‐, DNA‐ and RNA‐based vaccines (2004) (115)
Microparticles as potentially orally active immunological adjuvants. (1989) (113)
Comparison of poly(DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. (1993) (113)
Microparticles for intranasal immunization. (2001) (112)
The preparation and characterization ofpoly(lactide-co-glycolide) microparticles: III. Microparticle/polymer degradation rates and the in vitro release of a model protein (1994) (112)
Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells (1999) (105)
Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine (2001) (105)
Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. (2012) (103)
Delivery systems and adjuvants for oral vaccines (2006) (101)
The intestinal uptake of particles and the implications for drug and antigen delivery. (1996) (98)
Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. (1997) (95)
Investigation of the nasal absorption of biosynthetic human growth hormone in sheep—use of a bioadhesive microsphere delivery system (1990) (94)
A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. (2006) (94)
Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. (1995) (90)
Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. (1995) (89)
MF59 Is a Safe and Potent Vaccine Adjuvant for Flu Vaccines in Humans: What Did We Learn During Its Development? (2007) (89)
Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine (1997) (87)
The identification of plant lectins with mucosal adjuvant activity (2001) (85)
The impact of size on particulate vaccine adjuvants. (2014) (85)
Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. (2009) (85)
Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. (1997) (85)
Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. (1997) (84)
Microparticulate absorption from the rat intestine (1994) (84)
Cationic microparticles are a potent delivery system for a HCV DNA vaccine. (2004) (83)
A practical approach to the use of nanoparticles for vaccine delivery. (2006) (83)
Mucosal immunogenicity of plant lectins in mice (2000) (83)
Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene (2006) (83)
MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020) (2009) (82)
Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. (2001) (79)
Towards an evidence based approach for the development of adjuvanted vaccines. (2017) (79)
Conference Science Medal Lecture: Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration * (1998) (79)
A comparison of anionic nanoparticles and microparticles as vaccine delivery systems (2008) (79)
Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. (2013) (78)
Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. (2004) (77)
A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. (2002) (76)
Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins (2005) (76)
Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. (2003) (76)
Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. (2017) (74)
Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization. (1989) (73)
Targeting of drugs and vaccines to the gut. (1994) (72)
Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization (2015) (72)
Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection. (2020) (71)
Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. (2006) (70)
Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection (1996) (69)
Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. (2001) (69)
The Preparation, Characterization, and Evaluation of Cationic Microparticles for DNA Vaccine Delivery (2001) (69)
Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles (2003) (63)
Intranasal Immunization of Mice with Influenza Vaccine in Combination with the Adjuvant LT-R72 Induces Potent Mucosal and Serum Immunity Which Is Stronger than That with Traditional Intramuscular Immunization (1999) (63)
Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. (1993) (61)
Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles. (2001) (61)
Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. (2004) (60)
Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations (2003) (58)
The safety of vaccines (2004) (57)
An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles. (2005) (57)
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines (2021) (56)
Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. (2004) (56)
The Effect of CTAB Concentration in Cationic PLG Microparticles on DNA Adsorption and in Vivo Performance (2003) (56)
The continued advance of vaccine adjuvants - 'we can work it out'. (2020) (54)
Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models. (1998) (52)
A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. (1998) (52)
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines (2021) (52)
Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. (2003) (52)
The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. (2008) (52)
Charged polylactide co-glycolide microparticles as antigen delivery systems (2004) (51)
Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. (2006) (51)
Intestinal absorption of proteins and macromolecules and the immunological response. (1988) (51)
Adsorption of a Novel Recombinant Glycoprotein from HIV (Env gp120dV2 SF162) to Anionic PLG Microparticles Retains the Structural Integrity of the Protein, Whereas Encapsulation in PLG Microparticles Does Not (2004) (50)
A comparison of alternative methods for the determination of the levels of proteins entrapped in poly(lactide-co-glycolide) microparticles (1995) (49)
Recent developments in vaccine delivery systems. (2001) (48)
Oral Delivery of Vaccines (1992) (45)
Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. (2012) (45)
Nasal Absorption Enhancers for Biosynthetic Human Growth Hormone in Rats (1990) (44)
The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility. (1997) (43)
Characterization of Human Immunodeficiency Virus Gag-Specific Gamma Interferon-Expressing Cells following Protective Mucosal Immunization with Alphavirus Replicon Particles (2005) (43)
Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae. (1995) (43)
Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. (2000) (42)
Zero order release of protein from poly(d,l-lactide-co-glycolide) microparticles prepared using a modified phase separation technique (1995) (42)
The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance. (2015) (41)
Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. (2014) (41)
Genetically detoxified mutants of heat‐labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T‐cell responses against HIV‐1 gag‐p55 (2000) (41)
MF59: A Safe and Potent Adjuvant for Human Use (2006) (40)
Novel approaches to pediatric vaccine delivery. (2006) (40)
Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. (2002) (39)
Mannosylation of LNP results in improved potency for self-amplifying RNA (SAM) vaccines. (2019) (38)
The immunogenicity of a model protein entrapped in poly(lactide-co-glycolide) microparticles prepared by a novel phase separation technique (1994) (37)
Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. (2017) (37)
Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. (1996) (36)
Oral Administration of Influenza Vaccine in Combination with the Adjuvants LT-K63 and LT-R72 Induces Potent Immune Responses Comparable to or Stronger than Traditional Intramuscular Immunization (2001) (35)
Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines (2016) (35)
Immunological Implications of the use of Plant Lectins for Drug and Vaccine Targeting to the Gastrointestinal Tract (2004) (35)
Recent developments in vaccine delivery systems (2001) (35)
An alternative renewable source of squalene for use in emulsion adjuvants. (2011) (34)
Protection of Rhesus Monkeys by a DNA Prime/Poxvirus Boost Malaria Vaccine Depends on Optimal DNA Priming and Inclusion of Blood Stage Antigens (2007) (33)
Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines. (2021) (33)
MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine (2012) (32)
Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. (1999) (32)
The preparation, characterization and pre-clinical evaluation of an orally administered HIV-I vaccine, consisting of a branched peptide immunogen entrapped in controlled release microparticles (1995) (31)
Effect of L-α-lysophosphatidylcholine on the nasal absorption of human growth hormone in three animal species (1991) (31)
Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. (2001) (31)
Flow cytometry: an alternative method for direct quantification of antigens adsorbed to aluminum hydroxide adjuvant. (2011) (31)
Development of a potent Zika virus vaccine using self-amplifying messenger RNA (2020) (30)
Innate immunity and biodefence vaccines (2003) (30)
Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model. (2014) (30)
Combination Vaccines (2011) (29)
Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin. (1993) (29)
Rational Design of Adjuvant for Skin Delivery: Conjugation of Synthetic β-Glucan Dectin-1 Agonist to Protein Antigen. (2015) (29)
Controlled release microparticles for oral immunization (1994) (29)
Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein. (1992) (28)
Cholera toxin B subunit (CTB) entrapped in microparticles shows comparable immunogenicity to CTB mixed with whole cholera toxin following oral immunization (1995) (28)
Dose-Dependent Protection against or Exacerbation of Disease by a Polylactide Glycolide Microparticle-Adsorbed, Alphavirus-Based Measles Virus DNA Vaccine in Rhesus Macaques (2008) (27)
The quantitation of the absorption of microparticles into the intestinal lymph of Wistar rats (1994) (25)
Bioadhesive delivery systems for mucosal vaccine delivery (2010) (25)
A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. (2007) (24)
Are we entering a new age for human vaccine adjuvants? (2015) (23)
β7‐integrin‐independent enhancement of mucosal and systemic anti‐HIV antibody responses following combined mucosal and systemic gene delivery (2007) (23)
Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines (2020) (23)
Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs. (2015) (23)
Design of a novel vaccine nanotechnology-based delivery system comprising CpGODN-protein conjugate anchored to liposomes. (2020) (23)
Emulsion-Based Adjuvants for Improved Influenza Vaccines (2011) (22)
Biodegradable microparticles as oral vaccines. (1995) (22)
New Generation Vaccine Adjuvants (2015) (21)
Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide. (2016) (21)
The droplet size of emulsion adjuvants has significant impact on their potency, due to differences in immune cell-recruitment and -activation (2019) (20)
A modified process for preparing cationic polylactide-co-glycolide microparticles with adsorbed DNA. (2006) (20)
Characterization of antigens adsorbed to anionic PLG microparticles by XPS and TOF-SIMS. (2008) (20)
A two-stage strategy for sterilization of poly(lactide-co-glycolide) particles by γ-irradiation does not impair their potency for vaccine delivery. (2011) (19)
Biodegradable microparticles as a delivery system for the allergens of Dermatophagoides pteronyssinus (house dust mite): I. Preparation and characterization of microparticles (1995) (19)
Emulsions as Vaccine Adjuvants (2015) (19)
Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. (2006) (19)
Oral immunization with poly(lactide-co-glycolide) microparticles containing an entrapped recombinant glycoprotein (gD2) from herpes simplex type 2 virus (1998) (19)
Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination. (2008) (18)
Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates (2021) (18)
“World in motion” – emulsion adjuvants rising to meet the pandemic challenges (2021) (17)
Gaps in knowledge and prospects for research of adjuvanted vaccines. (2015) (17)
Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63). (2002) (17)
Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88. (2008) (17)
The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine. (2016) (16)
The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A. (2015) (16)
Adsorption onto aluminum hydroxide adjuvant protects antigens from degradation. (2020) (16)
Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice (2009) (15)
Recent advances in immunological adjuvants: the development of particulate antigen delivery systems. (1998) (15)
Multiplex immunoassay for in vitro characterization of acellular pertussis antigens in combination vaccines. (2016) (14)
Novel adjuvants and delivery systems for HIV vaccines (2002) (14)
Combinations of protein polysaccharide conjugate vaccines for intranasal immunization. (2002) (14)
Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine (2022) (14)
Adjuvants: progress, regress and pandemic preparedness (2007) (14)
Microparticles as vaccine delivery systems (2006) (14)
The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency (2021) (13)
Rational design of adjuvants for subunit vaccines: The format of cationic adjuvants affects the induction of antigen-specific antibody responses. (2020) (13)
Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want (2018) (13)
Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine. (2019) (13)
Emulsion based vaccine adjuvants (2013) (12)
The preparation and characterization of PLG nanoparticles with an entrapped synthetic TLR7 agonist and their preclinical evaluation as adjuvant for an adsorbed DTaP vaccine. (2016) (12)
Comparison of Poly(dl-Lactide-co-glycolide) and Polystyrene Microsphere Targeting to Intestinal M Cells (2003) (12)
MF59: A Safe and Potent Oil‐in‐Water Emulsion Adjuvant (2006) (11)
HIV and mucosal immunity (1991) (11)
Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines (2020) (11)
Formulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine. (2019) (10)
Biodegradable microparticles with an entrapped branched octameric peptide as a controlled-release HIV-1 vaccine. (1997) (10)
Stable Nanoemulsions for the Delivery of Small Molecule Immune Potentiators. (2018) (10)
Chapter 13 – MF59: A Safe and Potent Adjuvant for Human Use (2017) (9)
Optimizing gastrointestinal delivery of drugs. (1994) (9)
Antigen Delivery Systems I: Nonliving Microparticles, Liposomes, and Immune-Stimulating Complexes (ISCOMs) (2015) (9)
Mutant Heat-Labile Entertoxins As Adjuvants for CTL Induction (2000) (9)
Preparation of highly concentrated influenza vaccine for use in novel delivery approaches. (2013) (9)
Optimizing adjuvants for intradermal delivery of MenC glycoconjugate vaccine. (2017) (8)
Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines (2021) (8)
The Preparation and Physicochemical Characterization of Aluminum Hydroxide/TLR7a, a Novel Vaccine Adjuvant Comprising a Small Molecule Adsorbed to Aluminum Hydroxide. (2018) (7)
Immunopotentiators in Modern Vaccines : Second Edition (2016) (6)
Adjuvants: from serendipity to rational discovery. (2012) (6)
Polymeric Particles as Vaccine Delivery Systems (2017) (6)
Injectable PLGA Systems for Delivery of Vaccine Antigens (2012) (6)
Synthesis of protein conjugates adsorbed on cationic liposomes surface (2020) (5)
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice (2022) (5)
Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines (2020) (4)
Surface‐Charged Poly(Lactide‐Co‐Glycolide) Microparticles as Novel Antigen Delivery Systems (2006) (4)
Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. (2009) (3)
Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine (2022) (3)
Non-viral delivery of self-amplifying RNA (2012) (3)
MF59: A safe and potent oil in water emulsion adjuvant for influenza vaccines, which induces enhanced protection against virus challenge (2008) (3)
Concepts in Mucosal Immunity and Mucosal Vaccines (2014) (2)
Novel nonreplicating antigen delivery systems (1990) (2)
Pharmaceutical formulations as immunological adjuvants (1987) (2)
Infiltration of dendritic cells and antigen uptake in the muscle after injection of HIV-1 Env gp120 in adjuvant (2012) (1)
Enhancing and Tailoring the Immunogenicity of Vaccines with Novel Adjuvants (2012) (1)
Immunogenic compositions comprising microparticles comprising adsorbed toxoid antigen and containing a polysaccharide (2004) (1)
New developments in nasal vaccine delivery (1999) (1)
Extent of supercoiling in plasmid DNA vaccines (2006) (1)
Particulates and Lymphatic Drug Delivery (2019) (1)
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice (2022) (1)
Corrigendum to “The mechanism of action of MF59 – An innately attractive adjuvant formulation” [Vaccine 30 (2012) 4341–4348] (2013) (1)
Beta7-integrin independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery (41.1) (2007) (1)
Colloidal carriers as antigen delivery systems for oral immunisation (1990) (1)
Recent Developments in Nonliving Antigen Delivery Systems (2009) (1)
Maturation of Aluminium Adsorbed Antigens Contributes to the Creation of Homogeneous Vaccine Formulations (2023) (1)
Biophysical Characterization of Protein Antigens within Vaccine Formulations (2011) (1)
Intra-nasal Immunization with Filamentous Haemagglutinin Protects Mice Against Bordetella pertussis Infection (1993) (1)
Hiv vaccine-and application procedures (2003) (0)
Use of microparticles with adsorbed antigen for stimulating the immune defenses (1998) (0)
Compositions de peptides amphipatiques immunogènes (2009) (0)
Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response. (2022) (0)
A method for maintaining cell immune responses against proteins (2000) (0)
Bioadhesives and adjuvants use for the administration of antigens mucosally. (1999) (0)
A Self-Emulsified Adjuvant System Containing the Immune Potentiator Alpha Tocopherol Induces Higher Neutralizing Antibody Responses than a Squalene-Only Emulsion When Evaluated with a Recombinant Cytomegalovirus (CMV) Pentamer Antigen in Mice (2023) (0)
Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2 (2023) (0)
Microparticles and DNA Vaccines (2006) (0)
Flu shots with reduced amounts of squalene (2010) (0)
Author Correction: “World in motion” – emulsion adjuvants rising to meet the pandemic challenges (2023) (0)
Concentration and characterization of influenza antigen bulks for potential novel vaccine delivery applications (2011) (0)
Adjuvanted influenza vaccines and their potential role for vaccination of travelers (2010) (0)
Compositions de meningocoque assorties d'un adjuvant (2002) (0)
Genetic Assessment of B-cell Responses Following Immunization with HIV Env Protein and Adjuvants or SHIV (AD8) Infection in Nonhuman Primates (2014) (0)
Virionlignende feed particles to self-replicating RNA molecules (2011) (0)
Overview of vaccine adjuvants (2022) (0)
VaccineRhesus Macaques by a Nonclassical ISCOM Core-Specific Immune Responses Primed in Characterization of Hepatitis C Virus (2001) (0)
Microemulsions a macromolecules et microparticules adsorbees (2000) (0)
Flu vaccines that include combinations of particulate adjuvants and immunopotentiating (2006) (0)
Vaccine in Rhesus Macaques Alphavirus-Based Measles Virus DNA Glycolide Microparticle-Adsorbed , Exacerbation of Disease by a Polylactide Dose-Dependent Protection against or (2008) (0)
MRI/PET multimodal imaging of the innate immune response in skeletal muscle and draining lymph node post vaccination in rats (2023) (0)
Cationic Microparticles and Emulsions As Effective Delivery Systems for Immune Stimulatory CpG DNA (2004) (0)
Use of polymers of hyaluronic acid for mucosal release of vaccines and adjuvants (1999) (0)
Particulates and microemulsions with adsorbed microparticles. (2000) (0)
Use of bioadhesives and adjuvants for mucosal application of antigenic (1999) (0)
immunogenic compositions based on biodegradable microparticles comprising a diphtheria toxoid and tetanus. (2004) (0)
Procedure for cellular immune responses proteins. (2000) (0)
Influenza vaccines containing combinations of particulate adjuvants, and immune enhancers (2006) (0)
Microparticles comprising polynucleotides adsorbed on the surface of microparticles or trapped inside thereof (2004) (0)
A process for the production of IGF-I, sustained release formulations (1998) (0)
“World in motion” – emulsion adjuvants rising to meet the pandemic challenges (2021) (0)
Conclusions—“Getting Better” (2017) (0)
Vaccine adjuvants 1 (2015) (0)
Distinctive innate immune signatures at the injection site predict the adjuvant-mediated boost of adaptive responses towards a flu subunit vaccine. (106.9) (2011) (0)
Microparticles for administration of heterologous nucleic acid (2001) (0)
Compositions d'adjuvants (2002) (0)
Vaccine adjuvants 2 (2015) (0)
Compositions de microparticules et procede de fabrication desdites compositions (2001) (0)
Theintestinal uptake ofparticles andtheimplications for drugandantigen delivery (1996) (0)
Emerging concepts in the science of vaccine adjuvants (2021) (0)